Vildagliptin

Catalog No.S3033 Batch:S303301

Print

Technical Data

Formula

C17H25N3O2

Molecular Weight 303.4 CAS No. 274901-16-5
Solubility (25°C)* In vitro DMSO 60 mg/mL (197.75 mM)
Water 60 mg/mL (197.75 mM)
Ethanol 60 mg/mL (197.75 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.
Targets
DPP-4 [1]
(Cell-free assay)
2.3 nM
In vitro

Vildagliptin is the most stable DPP-IV inhibitor, binding in the S1- and S2-catalytic sites of DPP-IV, possessing a P-1 site transition-state mimetic. [1]

In vivo

Vildagliptin(orally dosed with 10 μmol/kg) is a potent, orally active inhibitor of plasma DPP-IV activity that provides increased levels of GLP-1 in an oral glucose tolerance test (OGTT) with Obese male Zucker rats. Vildagliptin orally dosed with 10 μmol/kg both significantly decreases glucose excursions and stimulates insulin secretion in Obese male Zucker rats. Maximum inhibition of plasma DPP-IV activity (95%) is observed approximately 2 hours postdose of Vildagliptin (1 μmol/kg, po) while >50% inhibition of DPP-IV is observed within 30 min postdose and persisted for >10 hours in normal Cynomolgus monkeys. [1] Vildagliptin(60 mg/kg) increases pancreatic beta cell mass through enhanced beta cell replication and reduced apoptosis, and the increased beta cell mass is sustained for 12 days after vildagliptin washout. [2] Vildagliptin administrated at doses of 10 mg/kg for 32 weeks protects nerve fiber loss in streptozotocin (STZ)-induced diabetic adult male Sprague Dawley rats. [3]

Protocol (from reference)

Animal Study:

[1]

  • Animal Models

    Obese male Zucker rats

  • Dosages

    10 μmol/kg

  • Administration

    Orally administrated at a single dose

Selleck's Vildagliptin has been cited by 11 publications

CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase [ Int J Mol Sci, 2024, 25(18)9760] PubMed: 39337249
DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice [ J Clin Invest, 2023, 133(12)e165933] PubMed: 37097759
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration [ Oncoimmunology, 2023, 12(1):2268257] PubMed: 37849962
Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation [ J Clin Med, 2023, 12(14)4632] PubMed: 37510747
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease [ Bioengineered, 2022, 13(2):3911-3929] PubMed: 35129424
Interrogation of kinase genetic interactions provides a global view of PAK1-mediated signal transduction pathways [ J Biol Chem, 2020, jbc.RA120.014831] PubMed: 33060198
Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration [ Brain Res Bull, 2019, 147:78-85] PubMed: 30738866
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity [ Cell Rep, 2017, 20(7):1692-1704] PubMed: 28813679
Molecular cloning and biochemical characterization of Xaa-Pro dipeptidyl-peptidase from Streptococcus mutans and its inhibition by anti-human DPP IV drugs. [ FEMS Microbiol Lett, 2016, 363(9)] PubMed: 27010012
The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. [Chakraborty S, et al. F1000 Res, 2015, 10.12688/f1000research.2-286.v3. eCollection 2013] PubMed: 25671081

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.